EUVIMED · CrossrefZeitschrift
NEJM Evidence
ISSN 2766-5526 · Massachusetts Medical Society
Neueste Artikel
Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)
E-Cigarettes with and without Behavioral Support for Smoking Cessation
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia
Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults
Cyclosporiasis Outbreak in Michigan, May–July 2026 — An Interim Report
Emergence of Babesiosis in Nova Scotia, Canada
A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making
Secukinumab for Giant Cell Arteritis
Outcomes of Pneumonia in ICUs in Low- and Middle-Income Countries — A Systematic Review
The Landscape of Genetically Driven Immune Disorders
Tobacco Product Use among U.S. Adults, 2023–2024
Antibodies Elicited by the 2025–2026 Influenza Vaccine
Multistate Infant Botulism Outbreak Associated with Powdered Infant Formula
A Randomized Trial of Targeted Hyponatremia Correction in Hospitalized Patients
Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children
Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn
Detection of Community Transmission of Clade Ib Mpox Virus in the United States
Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction
Minimally Invasive versus Open Pancreatoduodenectomy for Resectable Neoplasms
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites
From Kidney to Heart — and Beyond — SGLT2 Inhibitors in Chronic Kidney Disease
Validation of a Saliva Micro–RNA Signature for Endometriosis
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease
Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis
Cardiovascular-Focused Messaging to Improve Influenza Vaccination Rates
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Pharmacologic Therapies for Type 2 Diabetes
Prevalence and Prognostic Significance of COPD in Adults Younger than 50 Years of Age
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2
Semaglutide in Adults with Type 1 Diabetes and Obesity
EUVIMED